Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder

International Journal of Neuropsychopharmacology

Volumn 10, Issue 5, 2007, Pages 661-673

  Pierre Olié, Jean ^a   Kasper, Siegfried ^b  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Agomelatine; Antidepressants; Major depressive disorder

Indexed keywords

AGOMELATINE; HORMONE RECEPTOR STIMULATING AGENT; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; PLACEBO; SEROTONIN 2C ANTAGONIST; ACETAMIDE DERIVATIVE; ANTIDEPRESSANT AGENT; MELATONIN RECEPTOR; SEROTONIN 2C RECEPTOR;

ADULT; ARTICLE; BREAST TENDERNESS; CARPAL TUNNEL SYNDROME; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; EJACULATION DISORDER; FATIGUE; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; IMPOTENCE; INFECTION; INFLUENZA; INTERACTIVE VOICE RESPONSE SYSTEM; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD; MULTICENTER STUDY; NAUSEA; NIGHTMARE; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIUS FRACTURE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SCORING SYSTEM; SLEEP; STATISTICAL SIGNIFICANCE; SUICIDE ATTEMPT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; XEROSTOMIA; ADOLESCENT; AGED; ANALYSIS OF VARIANCE; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG POTENTIATION; HOSPITALIZATION; MIDDLE AGED; TIME;

ACETAMIDES; ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, MELATONIN; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 34948841405     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145707007766     Document Type: Article

References (65)

1. Alonso J, Angermeyer MC, Bernert S, et al., for the ESEMeD/MHEDEA 2000 Investigators (2004). Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica Scandinavica (Suppl.), 420, 21-27.
2. Anderson IM (2000). Selective serotonin reuptake inhibitors vs. tricyclic antidepressants: a meta-analysis of efficacy and tolerability. Journal of Affective Disorders 58, 19-36.
3. APA (2004). Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (4th edn) Washington, DC: American Psychiatric Association.
4. Armstrong SM, McNulty OM, Guardiola-Lemaitre B, Redman JR (1993). Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacology Biochemistry and Behavior 46, 45-49.
5. Barden N, Shink E, Labbe M, Vacher R, Rochford J, Mocaer E (2005). Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29, 908-916.
6. Bertaina-Anglade V, Mocaer E, Drieu la Rochelle C (2002). Antidepressant-like action of S 20098 (agomelatine) in the learned helplessness test. International Journal of Neuropsychopharmacology 5 (Suppl. 1), 65.
7. Bourin M, Mocaer E, Porsolt R (2004). Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. Journal of Psychiatry Neuroscience 29, 126-133.
8. Brotto LA, Gorzalka BB (2000). Melatonin enhances sexual behavior in the male rat. Physiology & Behavior 68, 483-486.
9. Brown R, Kocsis JH, Caroff S, Amsterdam J, Winokur A, Stokes PE, Frazer A (1985). Differences in nocturnal melatonin secretion between melancholic depressed patients and control subjects. American Journal of Psychiatry 142, 811-816.
10. Cheeta S, Ruigt G, van Proosdij J, Willner P (1997). Changes in sleep architecture following chronic mild stress. Biological Psychiatry 41, 419-427.
11. Claustrat B, Chazot G, Brun J, Jordan D, Sassolas G (1984). A chronobiological study of melatonin and cortisol secretion in depressed subjects: plasma melatonin, a biochemical marker in major depression. Biological Psychiatry 19, 1215-1228.
12. Clayton AH, Zajecka J, Ferguson JM, Filipiak-Reisner JK, Brown MT, Schwartz GE (2003). Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. International Clinical Psychopharmacology 18, 151-156.
13. Clerc G (for the Milnacipran/Fluovoxamine Study Group) (2001). Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluovoxamine. International Clinical Psychopharmacology 16, 145-151.
14. CPMP (2002). Note for the guidance on clinical investigation of medicinal products in the treatment of depression. Committee for Proprietary Medicinal Products.
15. CPMP (2001). Notes to consider on missing data. CPMP/EWP/1776/99. Committee for Proprietary Medicinal Products.
16. Danish University Antidepressant Group (1986). Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berlin) 90, 131-138.
17. Danish University Antidepressant Group (1990). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders 18, 289-299.
18. EMEA (European Agency for the Evaluation of Medicinal Products) (2005). Cymbalta European Public Assessment Report 2005. (http://www.emea.eu. int/humandocs/Humans/EPAR/cymbalta/cymbalta.htm). Accessed 6 April 2007.
19. Fava M, Evins E, Dorer D, Schoenfeld D (2003). The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychotherapy and Psychosomatics 72, 115-127.
20. Ferguson JM (2001). SSRI antidepressant medications: adverse effects and tolerability. Primary Care Companion to the Journal of Clinical Psychiatry 3, 22-27.
21. Ferguson JM, Shrisvastava RK, Stahl SM, Hartford JT, Borian F, Ieni J, McQuade RD, Jody D (2001). Re-emergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefadozone and sertraline. Journal of Clinical Psychiatry 62, 24-29.
22. Gorka Z, Moryl E, Papp M (1996). Effect of chronic mild stress on circadian rhythms in the locomotor activity in rats. Pharmacology Biochemistry and Behavior 54, 229-234.
23. Gruenberg AM, Goldstein RD (2003). Mood disorders: depression. In: Tasman A, Kay J, Lieberman JA (Eds.), Psychiatry (2nd edn) (pp. 1207-1236). Chichester: John Wiley & Sons.
24. Gurevich I, Tamir H, Arango V, Dwork AJ, Mann JJ, Schmauss C (2002). Altered editing of serotonin 2c receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron 34, 349-356.
25. Hamilton M (1960). A rating scale for depression. Journal of Neurology Neurosurgery & Psychiatry 23, 56-62.
26. Hanoun N, Mocaër E, Boyer PA, Hamon M, Lanfumey L (2004). Differential effects of the antidepressant agomaletine (S 20098) vs. fluoxetine on 5HT1A receptors in the rat brain, Neuropharmacology 47, 515-526.
27. Hindmarch I, Kimber S, Cockle SM (2000). Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. International Clinical Psychopharmacology 15, 305-318.
28. Judge R, Parry MG, Quail D, Jacobson JG (2002). Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. International Clinical Psychopharmacology 17, 217-225.
29. 2c agonists mimic the effect of light pulses on circadian rhythms. Brain Research 806, 257-270.
30. Kennedy SH, Eisfeld BS, Meyer JH, Bagby RM (2001). Antidepressants in clinical practice: limitations of assessment methods and drug response. Human Psychopharmacology: Clinical and Experimental 16, 105-114.
31. Kennedy SH, Emsley R (2006). Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. European Neuropsychopharmacology 16, 93-100.
32. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS (2003). The epidemiology of major depressive disorder. Results from the National Comorbidity Survey Replication (NCS-R). Journal of the American Medical Association 289, 3095-3105.
33. Khan A, Khan SR, Walens G, Kolts R, Giller EL (2003). Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 28, 552-557.
34. Khan A, Kolts RL, Thase ME, Krishnan KRR, Brown W (2004). Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. American Journal of Psychiatry 161, 2045-2049.
35. Kirsch I, Moore TJ, Scoboria A, Nicholls SS (2002). The Emperor's new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention and Treatment 5, 23. (http://www.journals.apa.org/prevention/volume5/pre0050023a.html). Accessed 6 April 2007.
36. Krauchi K, Cajochen C, Mori D, Graw P, Wirz-Justice A (1997). Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. American Journal of Physiology 272, R1178-1188.
37. Leproult R, Van Onderbergen A, L'hermite-Baleriaux M, Van Cauter E, Copinschi G (2005). Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clinical Endocrinology 63, 298-304.
38. Lôo H, Hale A, D'haenen H (2002). Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2c antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. International Clinical Psychopharmacology 17, 239-247.
39. Mallo C, Zaidan R, Galy G, Vermeulen E, Brun J, Chazot G, Claustrat B (1990). Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection. European Journal of Clinical Pharmacology 38, 297-301.
40. Martinet L, Guardiola-Lemaitre B, Mocaer E (1996). Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent. Pharmacology Biochemistry and Behavior 54, 713-718.
41. Masand PS, Gupta S (1999). Selective serotonin-reuptake inhibitors: an update. Harvard Review of Psychiatry 7, 69-84.
42. Michelson D, Fava M, Amsterdam J, Apter J, Londborg P, Tamura R, Tepner RG (2000). Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. British Journal of Psychiatry 176, 363-368.
43. 2C receptor blockade. Psychopharmacology (Berlin) 177, 448-458.
44. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D (2003). The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine 2c receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. Journal of Pharmacology and Experimental Therapeutics 306, 954-964.
45. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I (2004). Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. International Clinical Psychopharmacology 19, 271-280.
46. 18FFDG PET studies. Psychiatry Research 91, 59-78.
47. Papp M, Gruca P, Boyer PA, Mocaer E (2003). Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 28, 694-703.
48. Pitrosky B, Kirsch R, Malan A, Mocaer E, Pevert P (1999). Organisation of rat circadian rhythms during daily infusion of melatonin or S20098, a melatonin agonist. American Journal of Physiology 277, R812-R828.
49. Quera Salva MA, Vanier B, Chapotot F, Bohic M, Moulin C, Lofaso F, Guilleminault C (2005). Effect of agomelatine on the sleep EEG in patients with major depressive disorder. European Neuropsychopharmacology 15 (Suppl. 3), S435.
50. Redman JR, Guardiola-Lemaitre B, Brown M, Delagrange P, Armstrong SM (1995). Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms. Psychopharmacology (Berlin) 118, 385-390.
51. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB (1998). Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biological Psychiatry 44, 77-87.
52. Rush AJ, Trivedi MH, Wisniewski SR (2006). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine 354, 1231-1242.
53. Simon M, Schmelting B, Molzër E, Fuchs E (2004). Agomelatine restores sleep EEG activity in chronically stressed tree shrews. Abstract 354.10, presented at the Society for Neurosciences.
54. Sonawalla SB, Fava M (2001). Severe depression: is there a best approach? CNS Drugs 15, 765-776.
55. Souetre E, Salvati E, Belugou JL, Prinquey D, Candito M, Krebs B, Ardisson JL, Darcourt G (1989). Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Research 28, 263-278.
56. Storosum JG, Elferink AJ, van Zwieten BJ, van den Brink W, Gersons BP, van Strik R, Broekmans AW (2001). Short-term efficacy of tricyclic antidepressants revisited : a meta-analytic study. European Neuropsychopharmacology 11, 173-180.
57. Thompson C, Franey C, Arendt J, Checkley SA (1988). A comparison of melatonin secretion in depressed patients and normal subjects. British Journal of Psychiatry 152, 260-265.
58. Trivedi MH, Fava M, Wisniewski SR (2006). Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine 354, 1243-1252.
59. Varcoe TJ, Kennaway DJ, Voultsios A (2003). Activation of 5-HT2C receptors acutely induces Per gene expression in the rat suprachiasmatic nucleus at night. Brain Research. Molecular Brain Research 119, 192-200.
60. Vestergaard P, Gram LF, Kragh-Sorensen P, Bech P, Reisby N, Bolwig TG (1993). Therapeutic potentials of recently introduced antidepressants. Danish University Antidepressant Group. Psychopharmacology Series 10, 190-198.
61. Wehr TA, Wirz-Justice A (1982). Circadian rhythm mechanisms in affective illness and in antidepressant drug action. Pharmacopsychiatria 15, 31-39.
62. Wirz-Justice A (1995). Biological rhythms in mood disorders. In: Bloom FE, Kupfer DJ (Eds.), Psychopharmacology: The Fourth Generation of Progress (pp. 999-1017). New York: Raven Press.
63. Yamada J, Sugimoto Y (2001). Effects of 5-HT(2) receptor antagonists on the anti-immobility effects of imipramine in the forced swimming test with mice. European Journal of Pharmacology 427, 221-225.
64. Yeleswaram K, McLaughlin LG, Knipe JO, Schabdach D (1997). Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. Journal of Pineal Research 22, 45-51.
65. Yous S, Andrieux J, Howell HE, Morgan PJ, Renard P, Pfeiffer B, Lesieur D, Guardiola-Lemaitre B (1992). Novel napthalenic ligands with high affinity for the melatonin receptor. Journal of Medicinal Chemistry 35, 1484-1486.